ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1181

Absence of Lymphoid Cells May Aggravate Macrophage-Mediated Kidney Injury but Improve Repair in Immunodeficient Mouse Model of Adenine-Induced CKD

Session Information

  • CKD: Mechanisms - 2
    October 25, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms

Authors

  • Petrillo, Federica, AstraZeneca R&D Cambridge, Cambridge, Cambridgeshire, United Kingdom
  • Mulay, Shrikant R., AstraZeneca R&D Cambridge, Cambridge, Cambridgeshire, United Kingdom
  • Woollard, Kevin, AstraZeneca R&D Cambridge, Cambridge, Cambridgeshire, United Kingdom
  • Miller, Lorraine, AstraZeneca R&D Cambridge, Cambridge, Cambridgeshire, United Kingdom
  • Tesan Tomic, Tajana, AstraZeneca R&D Gothenburg, Molndal, Västra Götaland, Sweden
  • Soderberg, Magnus, AstraZeneca R&D Gothenburg, Molndal, Västra Götaland, Sweden
  • Thomas, Aurelie, AstraZeneca R&D Cambridge, Cambridge, Cambridgeshire, United Kingdom
  • Laerkegaard Hansen, Pernille B., AstraZeneca R&D Gothenburg, Molndal, Västra Götaland, Sweden
  • Dearman, Matthew S., AstraZeneca R&D Cambridge, Cambridge, Cambridgeshire, United Kingdom
  • Ling, Stephanie, AstraZeneca R&D Cambridge, Cambridge, Cambridgeshire, United Kingdom

Group or Team Name

  • Early CVRM Renal Bioscience, AstraZeneca R&D.
Background

Myeloid and lymphoid subpopulations have shown to be both protective and mediators of kidney injury. Mechanisms of crosstalk between pro- and anti-inflammatory actions of these effector cells is still unclear.

Methods

NSG mice (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) are deficient in mature lymphocytes, in natural killer cell cytotoxic activity and in cytokine signalling. In the current study we established a novel NSG mouse model of kidney injury by inducing renal failure through dietary delivery of 0.15% adenine for 7 days, compared to C57BL/6N mice and examined response to recovery by removing adenine diet for 14 days. We used Image Mass Cytometry to label 34 markers of immune cell kidney network and kidney injury pattern in adenine versus controls in NSG mice.

Results

CKD was induced in NSG and C57BL/6N mice by feeding 0.15% adenine diet. NSG-CKD mice showed 12% and 17% weight-loss (WL) after 3 and 6 days, respectively, while C57BL/6N-CKD mice showed 10% WL after 7 days. Blood Urea Nitrogen (BUN) and plasma Creatinine were increased 2-fold in NSG-CKD than C57BL/6N-CKD mice with a considerable amount of urinary excreted kidney injury markers, KIM-1 and NGAL after 4 days of treatment. NSG-CKD mice showed downregulation of epithelial markers (Megalin, SGLT2, GLUT-1, NKCC2, E-Cadherin) and upregulated markers of fibrosis (αSMA, Collagen I, Vimentin) that was not seen in C57BL/6N-CKD mice. Immune profile of NSG-CKD mice revealed increased macrophage-based inflammation with upregulated F4/80, CD45, CD11b, CD206, and loss of innate and adaptive lymphocytes immune response, CD4 and MHCII. This suggests that lack of lymphoid cells in NSG mice leads to a perpetual recruitment of macrophage cells and a worsening damage to the kidney in CKD. Interestingly, unlike C57BL/6N-CKD mice, removing adenine diet after 4 days in NSG-CKD mice completely recovered kidney function (BUN, NGAL, KIM-1) at 14 days. More work is underway to phenotype lymphoid subpopulations which may aggravate injury but boost repair during recovery in adenine-induced CKD.

Conclusion

This data highlights the need to unravel the dichotomy of inflammatory actions of lymphoid subpopulations, as T-regulatory and cytotoxic T-cells in CKD.